Title |
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
|
---|---|
Published in |
Leukemia, January 2017
|
DOI | 10.1038/leu.2017.35 |
Pubmed ID | |
Authors |
L Rosiñol, A Oriol, A I Teruel, A L de la Guía, MaJ Blanchard, J de la Rubia, M Granell, MaA Sampol, L Palomera, Y González, MaA Etxebeste, R Martínez-Martínez, M T Hernández, F de Arriba, A Alegre, MaT Cibeira, MaV Mateos, J Martínez-López, J J Lahuerta, J San Miguel, J Bladé |
Abstract |
The phase III trial GEM05MENOS65 randomized 390 patients 65 years-old or younger with newly diagnosed symptomatic MM to receive induction with thalidomide/dexamethasone (TD), bortezomib/thalidomide/dexamethasone (VTD) and VBMCP/VBAD/bortezomib (VBMCP/VBAD/B) followed by ASCT with MEL-200. After ASCT a second randomisation was performed to compare thalidomide/bortezomib (TV), thalidomide (T) and alfa-2b-interferon (alfa2-IFN). Maintenance treatment consisted of TV (thalidomide 100 mg daily plus one cycle of i.v. bortezomib at 1.3 mg/m2 on days 1, 4, 8 and 11 every 3 months) versus T (100 mg daily) versus alfa2-IFN (3 MU three times per week) for up to three years. 271 patients were randomized (TV: 91; T: 88, alfa2-IFN: 92). The CR rate with maintenance was improved by 21% with TV, 11% with T and 17% with alfa2-IFN (P=NS). After a median follow-up of 58.6 months, the PFS was significantly longer with TV compared with T and alfa2-IFN (50.6 vs 40.3 vs 32.5 months, P=0.03). OS was not significantly different among the 3 arms. Grade 2-3 peripheral neuropathy was observed in 48.8, 34.4 and 1% of patients treated with TV, T and alfa2-IFN, respectively. In conclusion, bortezomib and thalidomide maintenance resulted in a significantly longer PFS when compared with thalidomide or alfa2-IFN. (N° EUDRA 2005-001110-41).Leukemia accepted article preview online, 23 January 2017. doi:10.1038/leu.2017.35. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 25% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Science communicators (journalists, bloggers, editors) | 1 | 25% |
Scientists | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 84 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 15 | 18% |
Researcher | 9 | 11% |
Student > Master | 6 | 7% |
Student > Bachelor | 6 | 7% |
Professor > Associate Professor | 5 | 6% |
Other | 19 | 23% |
Unknown | 24 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 38 | 45% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
Agricultural and Biological Sciences | 3 | 4% |
Nursing and Health Professions | 2 | 2% |
Biochemistry, Genetics and Molecular Biology | 2 | 2% |
Other | 7 | 8% |
Unknown | 27 | 32% |